Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, multicenter, randomized, global Phase Ib study of olverembatinib in patients with CML in chronic-phase (CP), accelerated-phase (AP), or blast-phase (BP) or with Philadelphia chromosome positive acute lymphoblastic leukemia , who are resistant or intolerant to at least two tyrosine kinase inhibitors (TKIs)

Next Previous
Trial Profile

Open-label, multicenter, randomized, global Phase Ib study of olverembatinib in patients with CML in chronic-phase (CP), accelerated-phase (AP), or blast-phase (BP) or with Philadelphia chromosome positive acute lymphoblastic leukemia , who are resistant or intolerant to at least two tyrosine kinase inhibitors (TKIs)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olverembatinib (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use

Most Recent Events

  • 11 Dec 2022 According to an Ascendis Pharma media release, from October 26, 2016, to September 30, 2022 (data cutoff date), 101 patients with CML-CP (n = 86) and CML-AP (n = 15) were enrolled and treated with olverembatinib in the trial.
  • 11 Dec 2022 Results published in an Ascendis Pharma media release.
  • 11 Dec 2022 According to an Ascendis Pharma media release, 5-year follow-up data from the trial were presented at the American Society of Hematology (ASH) 64th Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top